Exploring the consistency of the SF-6Dv2 in a breast cancer population

被引:9
作者
Ameri, Hosein [1 ]
Safari, Hossein [2 ]
Poder, Thomas [3 ]
机构
[1] Shahid Sadoughi Univ Med Sci, Hlth Policy & Management Res Ctr, Sch Publ Hlth, Dept Hlth Serv Management, Yazd, Iran
[2] Iran Univ Med Sci, Hlth Promot Res Ctr, Tehran, Iran
[3] Univ Montreal, Sch Publ Hlth, Dept Management Evaluat & Hlth Policy, Montreal, PQ, Canada
关键词
Consistency; SF-6Dv2; breast cancer; Iran; QUALITY-OF-LIFE;
D O I
10.1080/14737167.2021.1842734
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Short-Form Six-Dimension version 2 (SF-6Dv2) is a multi-attribute utility instrument that can be used in combination with the SF-36v2 (SF-6Dv2(SF-36)) or as an independent instrument in two forms: six questions (SF-6Dv2(ind-6)) and 10 questions (SF-6Dv2(ind-10)). The purpose of this research was to assess the consistency between the results of the SF-6Dv2(ind-6) and the SF-6Dv2(SF-36) in patients with breast cancer. Research design and methods: This cross-sectional study was carried out on 418 patients with breast cancer. The degree of agreement between the descriptive systems of instruments was calculated using Spearman's correlation coefficient, global consistency index (GCI), and identically classified index (ICI). Results: The average size of the Spearman's correlation coefficients between the descriptive systems of instruments was higher than 0.5. The results of the GCI revealed that the level of agreement between dimensions of the two instruments had a mean of 64.9 (range 32.45-86.8). The SF-6Dv2(SF-36) generates statistically higher values than does the SF-6Dv2(ind-6), and mean difference between the two instruments was 0.087 for model 3 and 0.027 for model 10. Conclusions: This study provided evidence that the SF-6Dv2(SF-36) and the SF-6Dv2(ind-6) may produce different answers from patients with breast cancer and lead to a small difference in utility values.
引用
收藏
页码:1017 / 1024
页数:8
相关论文
共 29 条
[1]   Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients [J].
Ameri, Hosein ;
Yousefi, Mahmood ;
Yaseri, Mehdi ;
Nahvijou, Azin ;
Arab, Mohammad ;
Sari, Ali Akbari .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (01) :89-96
[2]   Quality of life in patients with rheumatoid arthritis - Which drugs might make a difference? [J].
Blumenauer, B ;
Cranney, A ;
Clinch, J ;
Tugwell, P .
PHARMACOECONOMICS, 2003, 21 (13) :927-940
[3]   The estimation of a preference-based measure of health from the SF-36 [J].
Brazier, J ;
Roberts, J ;
Deverill, M .
JOURNAL OF HEALTH ECONOMICS, 2002, 21 (02) :271-292
[4]   Deriving a preference-based single index from the UK SF-36 Health Survey [J].
Brazier, J ;
Usherwood, T ;
Harper, R ;
Thomas, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1115-1128
[5]   A comparison of the EQ-5D and SF-6D across seven patient groups [J].
Brazier, J ;
Roberts, J ;
Tsuchiya, A ;
Busschbach, J .
HEALTH ECONOMICS, 2004, 13 (09) :873-884
[6]   Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2 [J].
Brazier, John E. ;
Mulhern, Brendan J. ;
Bjorner, Jakob B. ;
Gandek, Barbara ;
Rowen, Donna ;
Alonso, Jordi ;
Vilagut, Gemma ;
Ware, John E. .
MEDICAL CARE, 2020, 58 (06) :557-565
[7]  
Crawford B., 2001, VALUE HLTH, V4, P70
[8]   Exploring the Consistency of the SF-6D [J].
Ferreira, Lara N. ;
Ferreira, Pedro L. ;
Pereira, Luis N. ;
Rowen, Donna ;
Brazier, John E. .
VALUE IN HEALTH, 2013, 16 (06) :1023-1031
[9]  
Ferreira Lara Noronha, 2008, J Med Econ, V11, P215, DOI 10.3111/13696990801983524
[10]  
Fleiss J. L., 2013, Statistical Methods For Rates and Proportions